Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy

被引:44
作者
Gudbjartsson, Tomas [1 ]
Gyllstedt, Erik [1 ]
Pikwer, Andreas [1 ]
Jonsson, Per [1 ]
机构
[1] Univ Lund Hosp, Dept Cardiothorac Surg, S-22185 Lund, Sweden
关键词
D O I
10.1016/j.athoracsur.2008.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Higher operative risks after pneumonectomy for non-small cell lung cancer (NSCLC) have been reported after neoadjuvant chemotherapy or radiotherapy, or both. Patients who underwent pneumonectomy for NSCLC were evaluated for effect of neoadjuvant treatment on mortality and morbidity, especially bronchopleural fistula. Methods. Between 1996 and 2003, 130 consecutive patients underwent pneumonectomy: 35 received preoperative radiotherapy and chemotherapy (the neoadjuvant group), and 95 patients did not (the first-surgery group). Operative mortality and postoperative complications were compared between the groups. Results. Minor postoperative complications were comparable in both groups (p > 0.10). Five patients in the neoadjuvant group and 10 in the first-surgery group had serious complications (p = 0.55). Eight had bronchopleural fistulas (7 right and 1 left, p < 0.01); 3 were in the neoadjuvant group (p = 0.49). Three fistulas required reoperation. One patient in the first-surgery group died within 30 days postoperatively. Duration of symptoms (hazard ratio, 6.6; p = 0.01) and right-sided pneumonectomy (hazard ratio, 2.4; p = 0.05) were associated with an increased risk of bronchopleural fistula. Induction treatment, postoperative radiotherapy, or coverage of the bronchial stump did not increase the risk of bronchopleural fistulation. Survival at 1 and 5 years was comparable for the neoadjuvant and first-surgery groups: 74% and 46% vs 72% and 34%, respectively (p > 0.2). Conclusions. Pneumonectomy is a safe procedure with low operative mortality. Postoperative morbidity is significant, especially bronchopleural fistulas after right-sided pneumonectomy (11%). However, neither operative mortality nor morbidity appears to be directly associated with preoperative radiotherapy or chemotherapy.
引用
收藏
页码:376 / 382
页数:7
相关论文
共 40 条
[1]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[2]   Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 [J].
Albain, KS ;
Crowley, JJ ;
Turrisi, AT ;
Gandara, DR ;
Farrar, WB ;
Clark, JI ;
Beasley, KR ;
Livingston, RB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3454-3460
[3]   Pneumonectomy for non-Small cell lung cancer: predictors of operative morality and survival [J].
Alexiou, C ;
Beggs, D ;
Rogers, ML ;
Beggs, L ;
Asopa, S ;
Salama, FD .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 20 (03) :476-480
[4]   Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy [J].
Barlési, F ;
Doddoli, C ;
Torre, JP ;
Giudicelli, R ;
Fuentes, P ;
Thomas, P ;
Astou, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 28 (04) :629-634
[5]   Pneumonectomy for malignant disease: Factors affecting early morbidity and mortality [J].
Bernard, A ;
Deschamps, C ;
Allen, MS ;
Miller, DL ;
Trastek, VF ;
Jenkins, GD ;
Pairolero, PC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (06) :1076-1081
[6]   The new World Health Organization classification of lung tumours [J].
Brambilla, E ;
Travis, WD ;
Colby, TV ;
Corrin, B ;
Shimosato, Y .
EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (06) :1059-1068
[7]   Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival [J].
Bueno, R ;
Richards, WG ;
Swanson, SJ ;
Jaklitsch, MT ;
Lukanich, JM ;
Mentzer, SJ ;
Sugarbaker, DJ .
ANNALS OF THORACIC SURGERY, 2000, 70 (06) :1826-1831
[8]   Pulmonary resection after high-dose and low-dose chest irradiation [J].
Cerfolio, RJ ;
Bryant, AS ;
Spencer, SA ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2005, 80 (04) :1224-1230
[9]   Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer [J].
Daly, BDT ;
Fernando, HC ;
Ketchedjian, A ;
DiPetrillo, TA ;
Kachnic, LA ;
Morelli, DM ;
Shemin, RJ .
ANNALS OF THORACIC SURGERY, 2006, 82 (01) :227-231
[10]   Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [J].
Depierre, A ;
Milleron, B ;
Moro-Sibilot, D ;
Chevret, S ;
Quoix, E ;
Lebeau, B ;
Braun, D ;
Breton, JL ;
Lemarié, E ;
Gouva, S ;
Paillot, N ;
Bréchot, JM ;
Janicot, H ;
Lebas, FX ;
Terrioux, P ;
Clavier, J ;
Foucher, P ;
Monchâtre, M ;
Coëtmeur, D ;
Level, MC ;
Leclerc, P ;
Blanchon, F ;
Rodier, JM ;
Thiberville, L ;
Villeneuve, A ;
Westeel, V ;
Chastang, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :247-253